BLI-489 hydrate
CAS 623564-40-9 MFCD22374169
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, B, Bioactive Small Molecule Alphabetical Index, Detection and Quantitation, Diversification Ready Pharma-Developed Compounds, Immune Cell Signaling and Blood, Immune System Regulation, Immunomodulators and Antibiotics, Multi-Drug Resistance, Multi-Drug Resistance and Drug Metabolism, Pfizer Compounds, Reagents, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
- Approved Therapeutics/Drug Candidates, Cell Biology, Cell Signaling and Neuroscience, Detection and Quantitation, Immune Cell Signaling and Blood, Immune System Regulation, Immunomodulators and Antibiotics, Multi-Drug Resistance,
相关文献及参考
- Petersen, P.J., et al., Efficacy of piperacillin combined with the Penem β-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob. Agents Chemother. 53 , 1698-1700, (2009) 摘要
- Petersen, P.J., et al., Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem β-lactamase inhibitor BLI-489. Antimicrob. Agents Chemother. 53 , 370-384, (2009) 摘要
- Ruzin, A., et al., Resistance development profiling of piperacillin in combination with the novel β-lactamase inhibitor BLI-489. J. Antimicrob. Chemother. 65 , 252-257, (2010) 摘要